Models for disease progression in oncology can be used to predict clinical outcome, but these have not yet been applied for making predictions of cost effectiveness, or for predicting clinical outcome while considering key aspects such as toxicities, dose adjustments, and clinical treatment protocols.
Integrated systems, such as University of California Integrated Staging System (UISS), and Mayo Clinic stage, size, grade and necrosis (SSIGN) score are also used to predict clinical outcome.
If TMS is to be used to predict clinical improvements, then MT and fluctuation in MT are candidate measurements.
Much work continues to investigate the critical molecular biomarkers that can be used to predict clinical response to chemotherapy and/or targeted therapies as well as to identify which patients might be at increased risk for developing drug-specific side effects.
Such proliferation-promoting genes commonly appear in expression signatures of cancer, and sometimes they can be used to predict clinical outcomes in tumor patients [12], [15], [16].
Genome-wide expression profiling of tumors has become an important tool to identify gene sets and gene signatures that can be used to predict clinical endpoints, such as survival and therapy response [1], [2], [3], [5], [6], [7], [8], [9], [10], [11], [12].
Clinical antimicrobial susceptibility breakpoints are used to predict the clinical outcome of antimicrobial treatment.
To determine whether certain combinations of genetic markers can be used to predict the clinical source of the infection, we analyzed well documented and geographically homogenous clinical isolates using a comparative genomics approach.
Although these errors are computed over the entire time section, there are no time intervals over which the self prediction results are worse than those when the OTC are used to predict the clinical data.
Qualitative and semi-quantitative assessments are used to predict SSc clinical complications.
This study is designed to investigate whether miR-125b levels can be used to predict the clinical response of patients with osteosarcoma (OS) to cisplatin-based chemotherapy.
